The essential role of the transporter ABCG2 in the pathophysiology of erythropoietic protoporphyria
Author(s) -
Pengcheng Wang,
Madhav Sachar,
Jie Lu,
Amina I. Shehu,
Junjie Zhu,
Jing Chen,
Ke Liu,
Karl E. Anderson,
Wen Xie,
Frank J. Gonzalez,
Curtis D. Klaassen,
Xiaochao Ma
Publication year - 2019
Publication title -
science advances
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.928
H-Index - 146
ISSN - 2375-2548
DOI - 10.1126/sciadv.aaw6127
Subject(s) - erythropoietic protoporphyria , ferrochelatase , phototoxicity , protoporphyrin , abcg2 , heme , transporter , porphyria , pharmacology , protoporphyrin ix , pathophysiology , photodynamic therapy , medicine , chemistry , atp binding cassette transporter , cancer research , biology , enzyme , biochemistry , endocrinology , in vitro , organic chemistry , porphyrin , gene
Erythropoietic protoporphyria (EPP) is an inherited disease caused by loss-of-function mutations of ferrochelatase, an enzyme in the heme biosynthesis pathway that converts protoporphyrin IX (PPIX) into heme. PPIX accumulation in patients with EPP leads to phototoxicity and hepatotoxicity, and there is no cure. Here, we demonstrated that the PPIX efflux transporter ABCG2 (also called BCRP) determines EPP-associated phototoxicity and hepatotoxicity. We found that ABCG2 deficiency decreases PPIX distribution to the skin and therefore prevents EPP-associated phototoxicity. We also found that ABCG2 deficiency protects against EPP-associated hepatotoxicity by modulating PPIX distribution, metabolism, and excretion. In summary, our work has uncovered an essential role of ABCG2 in the pathophysiology of EPP, which suggests the potential for novel strategies in the development of therapy for EPP.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom